Rapidly progressive disease in a castration-resistant prostate cancer patient after cabazitaxel discontinuation.
Anticancer Drugs
; 26(2): 236-9, 2015 Feb.
Article
em En
| MEDLINE
| ID: mdl-25340916
ABSTRACT
We report the case of a 51-year-old patient with metastatic prostate cancer at diagnosis and primary refractoriness to both androgen ablation therapy and docetaxel. At the time of cabazitaxel initiation, the patient had only osseous metastases and was constrained to a wheelchair because of bone pain. Ten cycles of cabazitaxel were administered, and a remarkable response was achieved, with improvement in biochemical markers, performance status, and bone scan findings. Two months after suspension of treatment by choice, the patient developed jaundice because of massive hepatic metastases and died after a few days because of hepatic failure.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Taxoides
/
Neoplasias de Próstata Resistentes à Castração
Limite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Anticancer Drugs
Assunto da revista:
ANTINEOPLASICOS
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Itália